Finally, finally the FDA has announced that it will stop the most blatant of the conflict of interest problems that has so discredited its operations. This comes only after severe pressure from Congress caused by a public ever more disgruntled by Big Pharma’s open control of the FDA.
Under the new guidelines, any scientist or physician who has $50,000 or more in financial ties to a company over the past 12 months, including stock or consulting arrangements, would be barred from panels evaluating that company’s products. Those who have received less than $50,000 in the previous year might be allowed to participate in the discussion but could not vote.
No date was actually announced for this to happen!